By Kendall Martinez-Wright, Elizabeth Lovinger, and De’Ashia Lee Many people recognize advances the LGBTQ+ community has made in the United States and other countries, including the freedom to marry their partners, sexual orientation and gender identity protections, and the fact…
By Lynette Mabote-Eyde and Mike Frick Too often, major scientific advancements against tuberculosis (TB) get lost on the long and winding road of policy translation into practice. TB preventive treatment (TPT) has faced decades of dislocation between progressive global World…
This year’s edition of TAGline commemorates TAG’s 30th anniversary, and these articles explore TAG’s work over the years: what we've accomplished, what we've learned, the continuing obstacles to progress, and what comes next.
As public health leaders, researchers, and civil society activists acting in solidarity with communities affected by tuberculosis (TB), we are dismayed by the continued global backslide in progress against history’s oldest pandemic.
Storytelling is a tool that can help build understanding, support discussions between members of affected communities and other stakeholders, and aid in the identification of important issues and potential solutions. The storyboards on this page describe the experiences of people…
Treatment Action Group (TAG) unequivocally condemns the September 2022 U.S. District Court ruling in Fort Worth, Texas on the case Braidwood Management Inc. et al., v. Xavier Becerra et al., which ruled that the Affordable Care Act’s requirement that employers cover pre-exposure prophylaxis (PrEP) for HIV prevention was unconstitutional.
As the global Long-Acting Technologies Community Advisory Board (LAT CAB) representing vast civil society networks, and people living with and affected by malaria, HIV, tuberculosis, and the hepatitis C virus (HCV) across the world, we welcome the efforts leading to the development of an investigational long-acting injectable (LAI) formulation of ivermectin to fight malaria transmission, mdc-STM currently in preclinical stage, and developed by MedinCell.
It’s now easier than ever to prevent TB before it develops into active disease or spreads within communities.
HIV prevention research continues to rapidly evolve. The availability of pre-exposure prophylaxis (PrEP) has necessitated the development of new approaches to testing the efficacy of additional biomedical HIV prevention options. This handout was developed in collaboration with the Black AIDS…
HIV-specific broadly neutralizing antibodies (bNAbs) could have a role in treating, preventing, or even curing HIV. Some HIV-specific bNAbs are already being tested in clinical trials, both for prevention and treatment. This handout was developed in collaboration with the Black…